In vitro effect of fludarabine, cyclophosphamide, and cytosine arabinoside on chromosome breakage in fanconi anemia patients: Relevance to stem cell transplantation

International Journal of Hematology

Volumn 85, Issue 4, 2007, Pages 354-361

  Yabe, Miharu ^a   Yabe, Hiromasa ^a   Hamanoue, Satoshi ^b   Inoue, Hiroyasu ^c   Matsumoto, Masae ^c   Koike, Takashi ^d   Ishiguro, Hiroyuki ^d   Morimoto, Tsuyoshi ^d   Arakawa, Satoshi ^d   Ohshima, Toshio ^d   Masukawa, Atsuko ^d   Miyachi, Hayato ^a   Yamashita, Takayuki ^e   Kato, Shunichi ^a  

^a TOKAI UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c Kanagawa Children's Center   (Japan)

^d TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e GUNMA UNIVERSITY   (Japan)

Author keywords

Chromosome fragility test; Fanconi anemia; Fludarabine; Preconditioning; Stem cell transplantation

Indexed keywords

BUTADIENE DIEPOXIDE; CROSS LINKING REAGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DRUG METABOLITE; FLUDARABINE; MITOMYCIN C;

ARTICLE; CHROMATID; CHROMOSOME BREAKAGE; CHROMOSOME FRAGILITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; FANCONI ANEMIA; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PERIPHERAL LYMPHOCYTE; SENSITIVITY AND SPECIFICITY; STEM CELL TRANSPLANTATION;

ANTIMETABOLITES, ANTINEOPLASTIC; CELLS, CULTURED; CHROMOSOME BREAKAGE; CHROMOSOME FRAGILITY; CYCLOPHOSPHAMIDE; CYTARABINE; FANCONI ANEMIA; FEMALE; HUMANS; MALE; MYELOABLATIVE AGONISTS; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; VIDARABINE;

EID: 34547507874     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.06191     Document Type: Article

References (27)

1. Tischkowitz M, Dokal I. Fanconi anaemia and leukaemia: clinical and molecular aspects. Br J Haematol. 2004;126:176-191.
2. Auerbach AD, Rogatko A, Schroeder-Kurth TM. International Fanconi Anemia Registry: relation of clinical symptoms to diepoxybutane sensitivity. Blood. 1989;73:391-396.
3. Gluckman E, Devergie A, Schaison G, et al. Bone marrow transplantation in Fanconi anemia. Br J Haematol. 1980;45:557-564.
4. Gluckman E, Devergie A, Dutreix J. Radiosensitivity in Fanconi's anemia: application to the conditioning regimen for marrow transplantation. Br J Haematol. 1983;54:431-440.
5. Gluckman E, Auerbach AD, Horowitz MM, et al. Bone marrow transplantation for Fanconi anemia. Blood. 1995;86:2856-2862.
6. Socie G, Devegie A, Girinski T, et al. Transplantation for Fanconi's anaemia: long-term follow-up of fifty patients transplanted from a sibling donor after low-dose cyclophosphamide and thoraco-abdominal irradiation for conditioning. Br J Haematol. 1998;103:249-255.
7. MacMillan ML, Auerbach AD, Davies SM, et al. Haematopoietic cell transplantation in patients with Fanconi anaemia using alternate donors: results of a total body irradiation dose escalation trial. Br J Haematol. 2000;109:121-129.
8. Yabe M, Yabe H, Matsuda M, et al. Bone marrow transplantation for Fanconi anemia: adjustment of the dose of cyclophosphamide for preconditioning. Am J Pediatr Hematol Oncol. 1993:15:377-382.
9. Guardiola P, Pasquini R, Dokal I, et al. Outcome of 69 allogeneic stem cell transplantations for Fanconi anemia using HLA-matched unrelated donors: a study on behalf of the European Group for Blood and Marrow Transplantation. Blood. 2000;95:422-429.
10. Motwani J, Lawson SE, Darbyshire PJ. Successful HSCT using nonradiotherapy-based conditioning regimens and alternative donors in patients with Fanconi anaemia: experience in a single UK centre. Bone Marrow Transplant. 2005;36:405-410.
11. Futaki M, Yamashita T, Yagasaki H, et al. The IVS4 + 4 A to T mutation of the Fanconi anemia gene FANCC is not associated with a severe phenotype in Japanese patients. Blood. 2000;95:1493-1498.
12. Yagasaki H, Oda T, Adachi D, et al. Two common founder mutations of the Fanconi anemia group G gene FANCG/XRCC9 in the Japanese population. Hum Mutat. 2003;21:555.
13. Yagasaki H, Hamanoue S, Oda T, Nakahata T, Asano S, Yamashita T. Identification and characterization of novel mutations of the major Fanconi anemia gene FANCA in the Japanese population. Hum Mutat. 2004;24:481-490.
14. Breithaupt H, Pralle H, Eckhardt T, von Hattingberg M, Schick J, Loffler H. Clinical results and pharmacokinetics of high-dose cytosine arabinosides (HD ARA-C). Cancer. 1982;50:1248-1257.
15. Tseng WC, Derse D, Cheng YC, Brockman RW, Bennett LL Jr. In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol Pharmacol. 1982;21:474-477.
16. Arima N, Mizoguchi H, Shirakawa S, Tomonaga M, Takatsuki K, Ohno R. Phase I clinical study of SH L573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia and adult T-cell leukemia/lymphoma [in Japanese]. Gan To Kagaku Ryoho. 1999;26:619-629.
17. Berger R, Bernhaim A, Gluckman E, Gisselbrecht C. In vitro effect of the cyclophosphamide metabolites on chromosomes of Fanconi anemia: application to the conditioning regimen for bone marrow transplantation. Br J Haematol. 1980;45:565-568.
18. Zanis-Neto J, Flowers MED, Medeiros CR, et al. Low-dose cyclophosphamide conditioning for haematopoietic cell transplantation from HLA-matched related donors in patients with Fanconi anaemia. Br J Haematol. 2005;130:99-106.
19. Schroeder-Kurth TM, Zhu TH, Westphal I. Variation in cellular sensitivities among Fanconi anemia patients, non-Fanconi anemia patients, their parents and siblings, and control probands. In: Schroeder-Kurth TM, Auerbach AD, Obe G, eds. Fanconi Anemia: Clinical, Cytogenetic, and Experimental Aspects. Heidelberg, Germany: Springer-Verlag; 1989:105-136.
20. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for treatment of malignant and nonmalignant hematologic disease. Blood. 1998;91:756-763.
21. Bacigalupo A, Locatelli F, Lamino E, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant. 2005;36:947-950.
22. de la Fuente J, Reiss S, McCloy M, et al. Non-TBI stem cell transplantation protocol for Fanconi anemia using HLA-compatible sibling and unrelated donors. Bone Marrow Transplant. 2003;32:653-656.
23. Boyer MW, Gross TG, Loechelt B, Leemhuis T, Filipovich A, Harris RE. Low risk of graft-versus-host disease with transplantation of CD34 selected peripheral blood progenitor cells from alternative donors for Fanconi anemia. J Pediatr Hematol Oncol. 2003;25:890-895.
24. Yabe H, Inoue H, Matsumoto M, et al. Allogeneic haematopoietic cell transplantation from alternative donors with a conditioning regimen of low-dose irradiation, fludarabine and cyclophosphamide in Fanconi anaemia. Br J Haematol. 2006;134:208-212.
25. Auerbach AD, Flit K, Batish SD, Morales J, Berwick M. A 25-year perspective of the DEB test for Fanconi anemia: correlation of mosaicism with clinical outcome. Paper presented at the Sixteenth Annual Fanconi Anemia Research Fund Scientific Symposium; October 14-17, 2004; Cambridge, Mass. Abstract available at: http://www.fanconi.org/research/Symposium2004Abstracts/ Auerbach.pdf. Accessed February 6, 2007.
26. Deeg HJ, Socie G, Schoch G, et al. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood. 1996;87:386-392.
27. Alter BP. Radiosensitivity in Fanconi's anemia patients. Radiother Oncol. 2002;62:345-347.